Status: Recruiting
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Participants needed: 120
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Western Institute for Veterans ResearchUpdated: Apr 5, 2024Locations: 2
Eligibility criteria
Must be able to understand and provide written informed consent [+3]
Untreated cutaneous warts [+8]